Nature tourism tested as depression therapy
NCT ID NCT07180342
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether structured nature-based tourism activities can improve symptoms of major depressive disorder. Researchers will compare an intervention group that takes part in these activities with a control group receiving usual care, while both groups continue their regular antidepressant medication. The goal is to see if time in nature can boost mood and social functioning.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- nature-based tourism activities
- What this could lead to
- If it works, this could point toward a low-cost, non-drug way to ease depression symptoms alongside standard medication.
- What could go wrong
- This is a small, early-stage study with no blinding, so results may be influenced by placebo effects or other factors. The intervention is not a replacement for standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 86 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2025
- Expected to finish
-
Sep 2027
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 59 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Voluntarily participate in the study and sign the informed consent form; 2. Age between 18 (inclusive) and 60 (exclusive) at the screening period; 3. Meet the DSM-5 diagnostic criteria for a Major Depressive Episode (MDE) at enrollment, based on medical records, clinical assessment, and the Mini-International Neuropsychiatric Interview (MINI version 7.0.2); 4. Hamilton Depression Rating Scale 17-item (HAMD-17) score ≥ 17 at both screening and baseline; 5. Physically stable based on medical history and vital signs (including blood pressure); 6. Deemed by the investigator to be capable of independently completing all assessment tools required by the study protocol and willing to comply with the trial procedures throughout the study period. Exclusion Criteria: 1. Current or past diagnosis of: schizophrenia, psychotic disorders (unless substance-induced or due to another medical condition), bipolar disorder, delusional disorder, paranoid personality disorder, schizoaffective disorder, borderline personality disorder, or other severe psychiatric comorbidities confirmed by medical history and structured clinical assessment using the Mini-International Neuropsychiatric Interview (MINI version 7.0.2); 2. Current or history of alcohol or substance abuse within the past year; 3. A score of ≥3 on item 3 (suicide) of the HAMD-17, suicide attempt within the past year, or clinically assessed significant suicide risk; 4. Depression secondary to other severe medical conditions (e.g., hypothyroidism, Parkinson's disease, etc.); 5. Cardiovascular diseases: stroke or myocardial infarction within the past year, hypertension (blood pressure \>140/90 mmHg), or clinically significant arrhythmia; 6. Other significant comorbid diseases that may interfere with the interpretation of study results or pose risks to participant health (e.g., cardiovascular, respiratory, gastrointestinal, hepatic, renal, or other systemic diseases), as determined by the investigator; 7. Current participation in an interventional study for Major Depressive Disorder, or participation in such a study within 30 days prior to screening; 8. Having visited Wulongtan Park, Baotu Spring Park and Daming Lake Park for a prolonged period (single stay ≥1 hour) within the past three years.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Major depressive disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Shandong Provincial Hospital Affiliated to Shandong First Medical University
NOT_YET_RECRUITINGJinan, Shandong, China
-
Shandong Provincial Hospital Affiliated to Shandong First Medical University
RECRUITINGJinan, Shandong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new oral drug lift severe depression?
- Magnetic pulses target teen depression
- Can an antipsychotic restore feelings in people with depression?
- Can intense brain zaps lift depression? scientists track blood flow in real time
- Can an ancient herbal capsule boost antidepressant power?
- Can talk therapy keep Esketamine's relief going?